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Abstract   
In this article we situate empirical research into women’s problematic experiences of anti-
depressant medication within broader debates about pharmaceuticalisation and the rise of the 
neurochemical self. We explore how women interpreted and problematized anti-depressant 
medication as it impeded their recovery in a number of ways. Drawing upon Foucauldian and 
feminist work we conceptualise anti-depressants as biotechnologies of the self that shaped 
how women thought about and acted upon their embodied (and hence gendered) 
subjectivities. Through the interplay of biochemical, emotional and socio-cultural effects 
medication worked to shape women’s self-in-recovery in ways that both reinscribed and 
undermined a neurochemical construction of depression. Our analysis outlines two key 
discursive constructions that focused on women’s problematization of the neurochemical self 
in response to the side effects of anti-depressant use. We identified how the failure of 
medication to alleviate depression contributed to women’s reinterpretation of recovery as a 
process of ‘working’ on the emotional self. We argue that women’s stories act as a form of 
subjugated knowledge about the material and discursive forces shaping depression and 
recovery. These findings offer a gendered critique of scientific and market orientated 
rationalities underpinning neurochemical recovery that obscure the embodied relations of 
affect and the social conditions that enable the self to change.  
 
Keywords: Depression, women, anti-depressants, discourse, emotion 
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Problematising	  the	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  subject	  of	  anti-­‐depressant	  
treatment:	  The	  limits	  of	  biomedical	  responses	  to	  women’s	  
emotional	  distress	  	  
 
Within critical social science approaches to mental health and illness there is a growing body 
of work that aims to make visible the biopolitical forces shaping knowledge, policy and 
practice around diagnoses, treatment and recovery (Abraham, 2010; Blackman, 2007; 
Busfield, 2006; Davidson, 2005; Horwitz, 2011; Pitts-Taylor, 2010; Rogers and Pilgrim, 
2010; Rose, 2007a; Smardon, 2008; Teghtsoonian, 2009; Williams et al., 2009). Our aim in 
this article is to further a gendered understanding of the biopolitics of depression by drawing 
upon interpretative research with women who problematized the truth claims of 
psychopharmacology as they recovered.  In this way we build upon feminist work that 
examines the gendered discourses and biomedical assemblages that shape women’s 
subjectivities as reflexive consumers and biocitizens (Blum and Stracuzzi, 2004; Ettorre and 
Riska, 1993; Fullagar, 2008b; Godderis, 2010; Lafrance, 2009; Metzl and Angel, 2004; 
O'Brien and Fullagar, 2009; Stoppard and McMullen, 2003; Ussher, 2011; Wiener, 2005).   
 
This article extends the first author’s previously published work on women’s construction of 
the ‘benefits’ of anti-depressant medication (Fullagar, 2009) to consider contrasting stories 
that identify ‘problematic’ issues. We acknowledge similarities with other research into the 
efficacy and consumption of medication that has explored issues of stigma, fears of 
dependency, placebo effects as well as ambivalence about the biochemical-sociocultural 
meaning of depression itself (Barr and Rose, 2008; Williams et al., 2008; Wilson, 2004). Our 
specific focus considers how women engage with anti-depressant medication as a bio-
technology of recovery that is prescribed by doctors to act upon the self as a neurochemical 
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subject. By consuming anti-depressants the depressed self is also acting upon and 
reinterpreting her relationship to self (as a complex socio-cultural interplay of identity, mind, 
body and emotion) in the process of recovery. In the context of the proliferation of expert and 
popular biochemical explanations of depression, we explore how women understand and 
enact this changing relationship to self-in-recovery as they experienced difficulties with anti-
depressant use and identified the limitations of a neurochemcial relation to self.  
 
Bringing together theoretical perspectives from Michel Foucault’s (1990; 1991) work on the 
government of self, more recent work on the rise of somatic subjectivity (Rose, 2007b) and 
feminist analyses of emotion/affect (Ahmed, 2004; Bendelow, 2009), we explore the 
discursive context of women’s interpretation of their own anti-depressant consumption. Our 
findings identify how women’s identities as neurochemical selves are both reinscribed and 
undermined as they question, critique or refuse the normalisation of anti-depressant use. First, 
we explore how women problematised the neurochemical self-in-recovery when medication 
failed to alleviate (and often exacerbated) emotional suffering through a range of side effects. 
The changing construction of selfhood generated ambivalence about, and for some resistance 
to, pharmacological solutions and biomedical expertise. We discuss how anti-depressants 
were found to be limited and limiting by women who had invested their emotional selves in 
neurochemical treatment regimes (seeking advice, adjusting doses to find the right balance, 
trying different antidepressants to find the right one, researching effects, negotiating with 
doctors).  
 
Second, we identified how women articulated recovery as a process of ‘working’ on the 
emotional self through non-medical practices (from therapy to yoga) that were transformative. 
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In contrast to a neurochemical discourse  women articulated a different construction that 
emphasised the every day experience of the emotional self-in-recovery (on woman's relation 
to self see,  O'Grady, 2005). For example, women identified how they thought about and 
acted upon themselves differently to monitor ‘warning signs’ and mood changes, develop 
strategies to manage different emotions and assert the self at work or home. While we 
identified these two distinct discourses a number of women did draw upon both discourses as 
they shifted between biomedical and everyday understandings of the complex process of 
recovery. We go on to argue that these stories can make visible a form of subjugated 
knowledge that questions the truth claims of psychopharmacology and acknowledges the 
emotional ‘work’ of recovery. We conclude by examining the limitations of biomedical-
scientific rationalities that position drug therapies as a thinkable solution to the 
neurochemically deficient self that is depressed.  
 
The	  Biopolitics	  of	  Women’s	  Emotional	  Life	  
 
We situate our empirical research within recent debates that have identified how the 
expansion of biopower through pharmaceutical markets, recovery oriented mental health 
policies and media discourses have contributed to the pharmacaueticalisation of everyday 
(Healy, 2004; Karp, 2006; Kramer, 1993; Rose, 2007b; Smardon, 2008; Williams et al., 2008; 
Williams et al., 2009). Rose (2007a) argues that molecular science has produced new ways of 
understanding and treating problems of ‘the mind’ in somatic terms (as a form of 
neurochemical deficit). Within this context ‘abnormal’ emotion and cognition have become 
targets for correction, improvement and even enhancement through pharmaceutical 
interventions. Yet, with growing evidence that there is little clinical difference in response to 
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anti-depressant drugs and placebos (Kirsch et al., 2008), critical and ethical questions 
continue to be raised about the practices that govern and regulate ‘emotional health’ through 
‘quick fix wonder drugs’ (Bendelow, 2010: 467; Rose, 2007b). The huge investment in drug 
trials, public health subsidies and personal consumption has occurred despite the growing 
body of research that critically questions the failure of antidepressants to effectively treat 
depression (Barr and Rose, 2008).  
 
Feminist work has also revealed how emotional distress has been governed through a 
gendered assemblage of diagnostic tools, therapeutic practices and biochemical knowledges 
that identify higher rates of diagnosis and prescription of anti-depressant medication for 
women (Godderis, 2010; Ussher, 2011). Women as a population are positioned as prone to 
depression due to a host of ‘factors’ that revolve around problematic biological bodies and 
fluctuating hormones (American Psychiatric Association, 2000). Hence, the pharmaceutical 
promise to alleviate women’s suffering and the growth of the anti-depressant market raises a 
particularly gendered problematic. While the medicalization of women’s misery through a 
range of drug treatments and diagnostic categorisation is well researched (see for example, 
Gabe and Lipshitz-Phillips, 1982), we approach the expansion of pharmacological treatment 
for depression from a different conceptualisation of power. Rather than view women as 
subject to power as a singularly oppressive force we take up Foucault’s notion of power as 
productive of different effects (Foucault, 1980). In this sense women who consume 
medication are not positioned as dupes of medical ideology nor are women who refuse 
medication somehow liberated from biopolitical institutions and meanings (Armstrong and 
Murphy, 2011; Lupton, 1997). Rather, we conceptualise women as active biomedical 
consumers who are urged to regulate their own emotions, illness identities and hence their 
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‘conduct’ as responsible and productive citizens in relation to biomedical authority and 
biotechnologies such as medication.  
 
Anti-depressants can be understood in Foucault’s terms as a ‘bio’technology of self that 
operates on the depressed subject’s relationship to her mind-body-emotions to attain a 
desired state of recovery. Recovery is itself a problematic term that is used in a number of 
ways to signify a return to ‘normality’ or the discovery of a ‘real or true’ self beneath 
depression (Keane, 2000). Hence, we understand recovery in a performative sense to involve 
a host of practices or technologies of self that shape individual conduct in relation to the 
discursive and gendered conditions of women’s lives. Technologies of self are described by 
Foucault as permitting ‘individuals to effect by their own means or with the help of others a 
certain number of operations on their own bodies and souls, thoughts, conduct, and way of 
being, so as to transform themselves in order to attain a certain state of happiness, purity, 
wisdom, perfection or immortality’ (1988). While medicalisation may help explain how 
women experiencing emotional distress come to be diagnosed with an illness identity known 
as depression, it is less helpful for thinking through the subject’s ‘doing’ of recovery as they 
actively negotiate a range of discourses about illness, identity and normality (see also, 
Busfield, 2006; Lupton, 1997). The concept of pharmaceuticalisation places greater emphasis 
on the complex range of institutional and cultural biopolitical forces that normalize anti-
depressants in relation to the individual’s desire for normality, success and happiness. Artist 
Justine Cooper provides a critical illustration of pharmaceuticalisation in her parody of drug 
advertising on her website for a fictious drug ‘HAVIDOL: when more is not enough. 
HAVIDOL is the first and only treatment for dysphoric social attention consumption deficit 
anxiety disorder DSACDAD (Cooper, 2009). Yet, as a number of feminists have identified, 
gendered discourses shape how women’s mental health or illness is regulated in particular 
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ways that emphasises their emotionality and position as ‘risky subjects’ with respect to the 
embodiment of care responsibilities (Godderis, 2010; Lupton, 1998; Ussher, 2011). These 
insights raise questions about how the neurochemical subject who is at the centre of anti-
depressant promotion and consumption is gendered and what these gendered effects might be 
in relation to women’s emotional lives. 
 
Although debilitated by the experience of depression women are positioned within the 
assemblage of mental health care services (medical practice, policy and products in the 
globalised market) as active biomedical consumers within advanced liberalism. In the 
Australian context of our research direct advertising of anti-depressant medication is not 
permitted but women can seek further information about medication through established 
websites that provide advice (for example, www.beyondblue.org.au) or through their own 
reading and discussion of Internet sites, popular magazines and social networks. Depressed 
subjects are expected to become help-seekers who should act upon the imperative to care for 
themselves (as they are expected to care for others and return to work). In this way, 
depressed women exercise agency by aligning their desires for recovery with expert and 
popular discourses about treatment and recovery pathways, or by refusing, resisting and 
seeking alternatives.  
 
We conceptualise this process through which women govern their conduct as selves-in-
recovery not merely in discursive terms but as profoundly embodied and emotional-affective. 
The self of depression is ‘swamped’ by affects (such as sadness, loss, misery, shame, fear 
and anger) that can render them unable to get out of bed or make everyday decisions. Hence, 
we conceive of emotional life as something women experience ‘through’ the mediating 
	   8	  
effects of socio-cultural relations.  In this sense the complexity of lived embodiment is 
understood to include but also exceed the valued qualities of rationality, control and self-
present knowledge (see also, Dormer and Davies, 2001; Fullagar, 2008a). As Sara Ahmed 
(2004: 4) states, ‘Emotions shape the very surfaces of bodies, which take shape through the 
repetition of actions over time, as well as through orientations towards and away from 
others’. In this sense the emotional self who desires medication to alleviate depression is not 
simply responding to emotions as an aspect of ‘inner subjectivity’ but is rather negotiating 
the relational and bioplitical context of identity (who am I as a woman in relation to my 
‘depression’ and who am I to become through anti-depressant use?). Next we outline the 
background to the research and the methodology employed. 
 
Women’s	  Recovery	  from	  Depression	  Project	  
 
Our research project developed in response to the identification of depression as a major 
public health issue for women and the need for a more sociological understanding of 
recovery. Depression has contributed greatly to the non-fatal burden of disease for women in 
Australia, and over the last decade anti-depressant prescriptions have dramatically increased 
(Commonwealth of Australia, 2007; 2009). To examine the gendered meanings of depression 
and recovery we conducted a large qualitative study in two eastern states of Australia with 80 
women. Participants were aged from 20 to 75 years and they self-identified as recovering or 
recovered from an experience of depression at some point in their lives. Within this diverse 
sample there were 72 women (90%) who had been prescribed and used medication at some 
point in their recovery. The same proportion (90%) had also sought help from their General 
Practitioner. Some doctors also offered counselling, or referred them to a psychiatrist or the 
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government subsidised program for psychological support. Despite taking anti-depressant 
medication, a large proportion (81%) of participants experienced a recurrence of depression 
in their lives and few considered themselves to be ‘fully recovered’. In this paper we focus 
only on the responses of approximately half of the large cohort (43 women) who identified a 
range of problems with anti-depressants, were critical of medication as a solution to 
depression or did not believe in drug therapies for various reasons. Elsewhere we have 
published work analysing the responses of thirty-one participants who identified largely 
positive effects of medication (Fullagar, 2009). Six women made no comment about 
medication in their interviews; half of these women had used medication and half had not. 
 
Ethical approval for the study was granted by Griffith University. Participants were recruited 
for the project from notices in community newspapers, fliers in health centres, e-mail lists 
and radio interviews. Given the exploratory nature of the inquiry a diagnosis of depression 
was not required of participants. Although the majority of women did receive a diagnosis 
(the range included mild, moderate, major, bipolar and postnatal depression). A number of 
women also described other experiences that affected their wellbeing, such as anxiety, panic 
attacks and sometimes psychosis. Semi-structured in- depth interviews were conducted by 
both of the authors within women’s homes or preferred locations and fully transcribed. 
Interviews probed women’s experiences of depression and what helped or impeded recovery, 
the metaphors they used to understand the changes in their lives and what they felt shaped 
women’s experiences in particular. In this article we focus on the responses women gave 
about medication use and its effects on their self-in-recovery.  Participants were 
predominantly Anglo-Celtic and heterosexual, with middle and working class backgrounds, 
and included women who were and were not mothers.  
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NVivo qualitative software was used to code and analyse comments specifically relating to 
anti-depressant medication. Initially we completed a thematic analysis to identify the issues 
women raised about their experiences with medication and problematic effects.   A second 
level of analysis was conducted in relation to the discourses that participants drew upon to 
articulate their understanding of anti-depressant medication in their recovery. We understand 
the research interview to be a relationship at that point in time through which a particular 
narrative of self was created, rather than a representation of ‘inner truth’. The narratives 
provided a means of exploring how participants interpreted their own experiences of 
medication in terms of the embodied side effects and their expectations of being 
treated/cured.  
 
The method of analysis brings together insights from a feminist approach to the discursive 
analysis of power–knowledge relations and a critical perspective on the interpretive practices 
that individuals use to make sense of their lives (Alvesson and Skoldberg, 2000; Mason, 
2002; Wetherell and Potter, 1988). Our analytic focus on ‘how’ women constitute their 
selves-in-recovery aims to move beyond the limitations of a biological-constructivist dualism 
that assumes medication has either biological or placebo effects.  In this way we critically 
examine questions about the efficacy and appropriateness of anti-depressant medication in 
the everyday context of women’s lives. We do not claim to represent all women’s 
experiences, but rather offer a partial glimpse into the biopolitical context that shapes self-
government in everyday life. In the second half of the article we examine two discursive 
constructions about the problematic effects of medication that were evident across women’s 
diverse experiences of depression and recovery. First, we identify a neurochemical relation to 
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the self-in-recovery where medication was problematised as means of treating the truth of 
depression as a chemical imbalance. Second, an alternate discourse about the limitations of 
medication was identified through the construction of the emotional self-in-recovery as 
situated within the context of everyday life.  
	  
Research	  Findings	  and	  Discussion	  
Problematising	  the	  neurochemical	  self-­‐in-­‐recovery	  
 
The notion of an anti-depressant ‘side effect’ is something of a misnomer as the forty three 
women in our sample identified a wide range of mild to severe problems that negatively 
affected and complicated their experience of recovery. The type, dose and length of 
medication use could worsen some depressive ‘symptoms’ (the inability to think clearly and 
lethargy), created unwanted changes (numbed emotions and lack of libido) and difficulties 
arose from reducing or changing medication (when it ‘stopped working’ or women desired to 
stop taking it). These embodied effects were often described and explained through a number 
of discourses as biochemical (changing serotonin levels) in origin, emotional-psychological 
(stemming from fear about dependency on drugs and perceived weakness of character) and 
social (linked to a reduced capacity to ‘function’ in relation to gender expectations in work-
leisure-family-community domains). Despite their very different experiences of depression 
which ranged in terms of type (eg., major episodes, post-natal) and duration (chronic over a 
life time or a one time experience) participants drew upon common discourses that were 
culturally available to them. While women drew upon a range of discursive constructions and 
acknowledged the social context of their lives, biochemical discourses were dominant in 
women’s own ‘explanatory models’ of depression as a neurochemical problem of imbalance, 
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lack or disruption. Hence, we explore within this theme how women with negative 
experiences of anti-depressant use drew upon, and also problematised in different ways, the 
normalised neurochemical self that figures in the discourse of recovery via treatment. The 
normalisation of biomedical treatment is not surprising in terms of the Australian help-
seeking context where medical professionals are positioned as a source of front line support 
within the health policy framework of ‘Medicare’ (Commonwealth of Australia, 2009). In 
addition to seeking medical advice most women actively researched information on the 
Internet, talked with friends and read popular literature on depressive experiences and 
medication use. Yet, the extent to which pharmacological solutions to depression are 
normalised in Australian culture was also questioned by Jorm et al (2000) a number of years 
ago. They identified preferences across the population for non-medical options and a mistrust 
of medication to solve mental health issues such as depression. The authors interpreted these 
responses as a problem of the population’s inadequate mental health literacy and called for 
better education. In contrast, we argue that this cultural context provides a compelling 
biopolitical background against which to examine more closely women’s interpretation of the 
problems of, and alternatives to, anti-depressant use in recovery. 
 
Reinscribing	  the	  neurochemical	  self	  
 
Women who were strongly invested in anti-depressants as the primary enabler of recovery 
found themselves in a difficult position when side effects worsened their emotional despair. 
This was more common in older women who had been prescribed medication for many years 
or those women who had struggled with depression for most of their lives as they tried 
different treatments and approaches to recovery.  For example, Janeka (30 years) who was 
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single and unemployed in a rural area with limited opportunities, still thought of herself as a 
‘resourceful person’ who could cope with difficult emotional situations. She had initially 
resisted taking medication, however, after a series of difficult life events culminating in a 
serious back injury she resorted to anti-depressant medication to help her with physical and 
emotional pain. At this point Janeka’s construction of self shifted from that of a ‘resourceful 
person’ to understanding herself as a biological subject with a neurochemical deficit. She 
stated: ‘you’re rebalancing chemicals in the brain, and… you know there’s something on a 
really biological level’. However, like many women who had struggled with the ongoing 
effects of depression Janeka also found herself trying various medications with little success.  
 
When Janeka eventually found an anti-depressant that ‘worked’, she then had to negotiate the 
complicating effects of medication on her life. She commented that ‘there were all these side 
effects; like I couldn’t stop eating … then I put on weight, which made me feel even more 
like shit’. Janeka was still taking medication at the time of the interview and said it was a 
‘slow recovery’ because of the ‘side effects’. At the time of interview she described herself 
as ‘70% recovered’ and continued to focus on increasing her biomedical expertise as a 
knowledgeable consumer of medication so she could recover further. Beverly (47 years) who 
was married and living in an outer suburban area had a similar experience although she had 
consumed anti-depressants for longer and was still taking them at the time of the interview. 
She had worked with her psychiatrist for a number of years trialling different anti-
depressants without sustained success. In the comment below Beverly articulated her fear 
that medication was failing to help restore her ‘functioning’ and this undermined her hope for 
recovery. 
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At first I used to believe ‘Oh yes, this is going to work and I’ll be better and I’ll 
be back on track of life’ you know ‘I’ll be functioning again’ and everything … 
now I think, I don’t have a lot of promise in them, like I’m a bit disheartened, I 
think ‘yeah okay, we’ll try this one, probably mightn’t work’ … and that’s a bit 
scary too, because I’m thinking ‘now medication doesn’t work, what is there? 
What else is there?’ because I put so much hope into the medication.  
 
Beverly described a ‘pattern’ she went through when she was prescribed a new drug by her 
psychiatrist. She would have a couple of weeks of feeling really ‘high’ and then she would 
come down with ‘a real crash’ and she would become ‘really depressed’ again. Beverly 
interpreted her ‘failure’ to respond to medication as a failure to ever be able to recover and 
manage her selfhood, ‘it was part of me and my make-up and that I just had to accept and get 
used to’. Encouraged by her doctors Beverly remained invested in a neurochemical relation 
to self and quest to find the right medication although she had begun to lose faith in the 
biomedical promise. The interpretation of the truth of the self as neurochemical worked to 
prevent some women from developing other kinds of self-understanding about their 
emotional life and social circumstances. 
 
The subject position of expert biomedical consumer in these instances is not necessarily 
relinquished due to the problematic effects of medication or loss of faith in treatment, but 
reinscribed through the ongoing hope or desire for a neurochemical fix. This desire to restore 
the neurochemical self does not reside ‘within’ individuals, rather it is an emotional or 
affective relation that is produced and circulated through the assemblage of discourses about 
treatment, consumer-doctor partnerships, promising new markets and policies aimed at 
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restoring a productive population (Ahmed, 2004; Rose, 2007a). For women who did lose 
faith and start to question the normalisation of medication within their recovery it was a 
difficult process to articulate their concerns and have these emotions acknowledged (eg., fear 
or anger).  Michelle (41 years) talked about how the ongoing practice of prescribing 
medication for her depression further undermined her sense of worth, 
 
I’ve been on this medication, which is almost 12 months.  And they won’t listen, 
and they say ‘No, you’re going to stay on the medication.’ … Sedating me too 
much … I feel like an underclass. 
 
Michelle was not able to hold down a job, was living alone in government housing, had little 
community involvement and had meals delivered to ensure that she would eat. The lack of 
available alternatives severely undermined Michelle’s sense of agency in recovery and this 
was compounded by the effects of medication and sense of injustice. This example illustrates 
how the focus on anti-depressant use and adjusting one’s ‘neurochemical deficits’ intersects 
with gendered discourses about recovery that invoke self-responsible care and the ‘good 
woman’ ideal (Stoppard, 2000; Ussher, 2011). By questioning biomedical expertise or 
expressing one’s loss of faith in the truth claims that underpin medication use, women also 
problematise how they have been positioned as compliant biocitizens. 
 
Side	  effects	  and	  emotional	  estrangement	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In this theme we explore how women interpreted medication to be problematic in terms of 
their emotional relation to self as they began questioning the authority invested in 
neurochemical explanations. The problematic experience of anti-depressants was described 
not just in terms of embodied side effects but also in relation to a feeling of ‘false security’ 
where medication failed to live up to its promise. Like a number of participants Robyn (25 
years) thought one of the antidepressants she was prescribed helped her mood for a while, 
however, after continued use it left her feeling numb and estranged from her emotions.  
 
They mess with my emotions. Sometimes I wouldn’t feel anything, so that really 
hindered my recovery … on the anti-depressants, at times I would not even know 
why I was feeling bad. Whereas when I wasn’t on them, I always knew.  
 
Robin who was unemployed and living with her partner in an outer suburban area had 
experienced depression since her late teens. After having taken medication for about one year 
she stopped after finding that anti-depressants sent her plummeting back into depression. She 
also felt that they left her feeling so emotionally disconnected that she engaged in self-harm, 
drank alcohol to numb herself further, or punched and cut herself to connect with some kind 
of feeling. Overall medication hindered Robyn’s recovery because she felt distanced from 
understanding her emotional responses to life situations. Women also spoke about how 
medication was unable to address or compounded the absence of pleasure or positive 
emotions in everyday life. In a similar way to Robyn, a number of women articulated the 
self-in-recovery not in purely neurochemical terms but through the language of emotional 
confusion, feeling like a ‘failure’ and being ‘out of control’ (suicidal thoughts).  
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While we are not suggesting a causal relationship there were seven participants who reflected 
upon how their ‘failure’ to get well intensified emotional distress to such an extent that they 
considered suicide. For example, Phoebe (43 years) was trialling a number of medications of 
which anti-depressants were one. She stated, ‘I was driving home this day and it was raining 
and there was a truck up ahead of me and it had stopped. And I thought “Mm…you know if I 
could drive under that truck, everyone would think it was an accident, and then that would be 
okay”’. It was not only that women feared harming themselves. After only one dose of 
medication that left her feeling estranged from herself Pam (44 years) feared what she might 
do to her children. In terms of the effects of depression and medication, women’s ‘failure to 
recover’ was articulated in relation to their feelings of success/failure as mothers, workers, 
partners and ‘self-responsible’ citizens who assume responsibility for the care of others. 
Compounding this was the inability of medication to alleviate distress or fulfil expectations 
of ‘cure’ which also forms part of the gendered context for such suicidal thinking. As Canetto 
and Lester (1998) argue suicide can be understood as an interpretive response to painful 
emotions that is underpinned by cultural scripts about women as weak and emotional. Anti-
depressants are proffered as a rational solution to help women overcome feelings of 
‘weakness and emotionality’, yet women identified the intensification of their fears of self-
harm, lack of trust in self and guilt in leaving others behind. These accounts suggest that 
women deployed a construction of the self-in-recovery that privileged an emotional relation 
to self. The failure of medication revealed the limitations of conceiving recovery as a 
pharmacological pathway out of a neurochemical problem. However, the normalisation of 
medication and the gendered context of women’s lives often meant that the failure of 
medication was interpreted as their own failure to successfully recover. In the next section 
we discuss how some women managed to deploy a construction of the emotional self-in-
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recovery that explicitly resisted, refused or rejected the normalisation of neurochemical 
subjecthood. 
 
Working	  on	  the	  emotional	  self-­‐in-­‐recovery	  
 
Being reflexive about the effect of the research ‘relationship’ on our findings we identified a 
patterned response in the interviews about what women felt ‘helped and hindered’ their 
recovery from depression. Many women initially drew upon a normalised discourse about 
seeking help from medical and psy-professionals, trying medication or seeking social support 
in self-help groups. When questioned further about what else they did that ‘helped’ their 
responses revealed a host of everyday practices and changes in work-family-leisure 
relationships that significantly influenced their emotional relation to self-in-recovery.  
This construction of recovery was often described as a process of ‘working on the self’ to 
enable change and resistance to normalised ideas about gender identity, relationships and 
also the value of medication. Some women clearly articulated their resistance to and refusal 
of pharmacological solutions to emotional problems, while for others both discourses co-
existed (often in an uneasy relationship). We suggest that the difference between these two 
responses is related to the length of time that women had not been using medication and had 
spent developing a different relation to self. However, the process of resisting was never 
simple and nor were women ‘self present’ subjects who consciously made consistent 
decisions about their emotional wellbeing. Rather, the emotional relation to the self-in-
recovery was fluid and required ongoing ‘work’ that sustained change in the subject’s self 
interpretation.  
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One of our younger participants illustrates this complex process of changing the emotional 
relation to self.  Jaguar (27 years) had tried to manage her depression without medication 
because she felt that anti-depressants ‘levelled’ her emotions out too much and she found it 
difficult to feel happy. For Jaguar, ceasing medication meant that she could feel her emotions 
rather than be shut off from them: ‘So, to go off it you feel kind of fun because you do have 
more feelings, or those feelings are more intense’. Yet at the time of interview, Jaguar was 
still taking anti-depressants because she feared the self that contemplated suicide when she 
was severely emotionally distressed. Jaguar was also going through a very challenging life 
event as she struggled with her emerging lesbian identity. Interestingly, when asked if she did 
anything else to help her recovery besides taking anti-depressants, she said that she did not. 
However, immediately after this statement she commented that she ‘worked hard on herself’ 
to understand her emotional relation to self rather than attempt to control unwanted emotions 
through medication. Jaguar stated that recovery ‘was really like a discipline’ and she made a 
job for herself everyday of things that she needed to keep trying to do. These included, 
exercising, eating well, laughing, dancing and finding new social connections in the gay and 
lesbian community. She also spoke of allowing herself to have ‘bad days too’ and was trying 
to deal with negative emotions rather than become overwhelmed by them. She also said that 
rather than doing things she felt ‘obligated’ to do she acted upon her desire where ‘the things 
to go and do are things I do because I want to’.  Jaguar described the shift in her desire to 
articulate a gendered (and sexual) identity that moved beyond the normalised expectations 
associated with what women should do, think and act in order to be valued. The ‘work’ of 
recovery was articulated in terms of self-discipline and self-care as it involved a different 
relation to  self	  where different (‘positive’) emotions enabled and were enabled by 
connection with others and pleasurable experiences of agency.  
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A number of women challenged and refused biomedical authority as a result of the failure of 
medication and the recognition that medical expertise alone would not help them recover. 
Thirteen women talked about the strategies they engaged in their quest to find non-medical 
practices of self-care. Sometimes they managed to cease taking anti-depressants in 
conjunction with their doctor, other times they ignored expert advice, reduced their doses as 
well as challenged medication as the primary treatment mode. Understanding how women 
create meaning about their medication use and negotiate biomedical expertise may provide 
useful insights for those professionals who adopt the unhelpful language of ‘non-compliance’ 
when women exercise agency to refuse (Egan et al., 2003).  
 
Women’s fear of being reliant on medication led some to decide to manage their recovery 
without it. Tayla (31 years) was initially prescribed anti-depressants after she had suicidal 
thoughts. She decided to stop taking anti-depressants after a conversation with another 
person who had a similar experience. Tayla reflected on her own experience, ‘Nup, I’m not 
going to be on medication for 5 or 6 years. I just went cold turkey…I can beat this with (the 
help of) husband, kids, friends…’. Tayla, who had been somewhat socially isolated in her 
rural community, enlisted the help of her friends who would drop around meals or mind the 
children so she could take time to soak in a bath. She also took a stand in regard to the 
unrealistic demands she felt were being placed on her in the workplace. Tayla’s response to 
the fear of becoming trapped in neurochemical selfhood changed the everyday gendered 
context that she identified as contributing to her emotional distress in the first place.  
 
Ironically the failure of anti-depressants treatment for many women opened up alternative 
ways of thinking about and practicing recovery. Allie (69 years), who lived through the era 
	   21	  
when barbiturates were prescribed to treat depression, challenged this form of treatment by 
refusing to take it because it sedated her too much.  
 
I thought no, this is no good, there must be something, something else. But I 
didn’t know what the something else could be and it wasn’t until many, quite a 
few years later that I learnt, yeah how to deal with depression ... And then it was a 
matter of dealing with it, I mean I learnt how to … live with it if you like, but it 
was many more years after that before I came through it. 
 
Over the thirty years since Allie was first diagnosed with depression, she has learned that her 
emotional distress was a signifier that something was amiss in her emotional life that she 
needed to address. During this time she has also learnt to ‘self nurture, count her blessings, 
journal and meditate’. Part of the self-nurturing is developing different embodied ways of 
living, 
 
I mean I think you can’t go past exercise, but it’s not the only answer, it’s very 
complex, depression is complex and also the overcoming it is complex, so you try 
lots of things until you find what works for you. 
 
Central to women’s struggle to interpret their changing sense of self-in-recovery was this 
negotiation of biochemical and emotional meanings about their experience. To move beyond 
the state of depression women, such as Allie above, talked about different technologies of 
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self that they deployed to help move them out of the stasis of depression. This change was 
not attributed to a neurochemical substance but rather to the emotional work that manifested 
in a new relation of care to the self that they experimented with and practiced over time. Such 
changes meant that women were less focussed on the biotechnologies of recovery (such as, 
managing medication doses, dealing with side effects and consultations with doctors). In 
contrast they talked about the importance of understanding their emotions (looking for 
warning signs about mood change, distinguishing feeling sad from a slide into depression, 
finding enjoyable experiences). In addition, they took action to change their embodied 
experience (joining choirs, taking up yoga or gardening, planning travel adventures, listening 
to music, playing team sport or walking by oneself). And they questioned social or gendered 
expectations about how they ‘ought’ to live (becoming assertive in relationships, having time 
out from motherhood, downshifting work or seeking new careers). Renata (38 years) talked 
about her changing relation to self, 
 
Because I notice that I haven’t done exercise, or something for myself, or a 
massage, or something like that; that’s when I start to go off the rails. And so 
what I do is, just say knowing my signs, is I kick in the self care. So … I 
mentioned the massage … or I cut my workload down.  
 
Women, like Renata and Allie, found another language through which to relate to their 
emotional selves that was founded in an experiential form of self-knowledge and care rather 
than neurochemistry. This relation to self required women to question the gendered ethics of 
care that accords women value for putting the needs of others (children, male partners and 
ageing parents) before their own. These findings highlight how women’s knowledge about 
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what works for them in the process of recovery largely remains a form of ‘subjugated 
knowledge’ within the contemporary biopolitical context (Foucault, 1997). At best non-
medical practices are considered to be a form of ‘self-help’ that women should responsibly 
engage in to ‘augment’ the primary role of anti-depressant treatment. And at worst they are 
dismissed as ‘anecdotal stories’ against the construction of gold standard ‘evidence’ 
associated with randomised treatment trials (despite the questions raised by placebo effects). 
We argue that anti-depressant treatment urges women to act upon their ‘faulty biochemistry’ 
to correct or improve the neurochemical self. Yet, the neurochemical self is not so easily 
improved and the effects are personal and social; the focus on changing biochemistry occurs 
at the expense of acknowledging the emotional and gendered context of depression that 
shapes women’s self-knowledge. If women’s experiences were taken seriously as an 
‘evidence base’ there would need to be a vastly different approach to knowledge in medical 
and therapeutic practice, education and community programs about mental health literacy. 
Ironically, the impetus for more critical debate at a personal and more broadly at a social 
level could very well be the ineffectiveness of pharmaceutical solutions and the limitations of 
scientific rationalities to understand the cultural complexities of emotional life. 
 
Concluding	  remarks	  
 
Our research set out to document the self interpretations of forty three women who felt 
highly ambivalent about the effectiveness of anti-depressants or were critical of ‘side effects’ 
that impeded their recovery. A number of older women had been caught in a cycle of 
recovery and relapse as they moved through the revolving door of drug trials and 
experimentation for over 20 or 30 years. With pressures relating to work and family many 
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mid-life and younger women desired a fast working remedy for their depression and yet they 
experienced complicating embodied effects and fears about dependency or recurrence. The 
problematic issues with anti-depressant treatment made alternative understandings of 
recovery ‘thinkable’ for some women, for others it reinscribed a neurochemical relation to 
self and a loss of hope in the possibility of recovery. Our findings identified two discursive 
constructions that figured predominantly in the responses of women concerning the 
neurochemcial and emotional self-in- recovery. The experience of side effects contributed to 
the problematization of the neurochemical self (often exacerbating distress) and a feeling of 
great ambivalence about pharmacological promises. Anti-depressants were critiqued in terms 
of the ‘false security’ they offered women who invested their emotional selves in 
biotechnologies of recovery (seeking advice, adjusting doses to find the right balance, trying 
different antidepressants to find the right one, researching effects, negotiating with doctors). 
These problems and limitations contributed to a different interpretation of recovery as a 
process of working on the emotional self (identifying warning signs of mood change, 
developing strategies to manage expectations, experiencing different emotions, asserting 
oneself). Women deployed a wide range of everyday practices (from therapy to yoga) that 
transformed their emotions through relations of self-discipline and care of the self (see also, 
Fullagar, 2008a; O'Grady, 2005).  
 
Many women recounted how their interpretation of emotional distress became more critical 
and relational as they sought out other ways to think about, relate to and act in relation to the 
self they desired to become. This included rediscovering the value of pleasurable leisure 
experiences that enabled time-space for oneself or as a means of social connectedness. 
Women also spoke of changing careers, downshifting from stressful jobs or leaving/starting 
relationships and questioning the gender expectations that had urged them to be ‘good 
	   25	  
women’ and put needs before their own desires (Stoppard, 2000). What signified this shift in 
understanding recovery were the different emotions that ‘moved’ and affected the embodied 
self in different ways that could not be reduced to biology, cognition or a purely 
constructionist notion of the body.  Ahmed (2004: 164-5 ) makes an insightful point about 
the significance of pleasurable emotions that has relevance for thinking about women’s 
entitlement to recover from depression in ways that they find helpful,   
 
Pleasure involves not only the capacity to enter into, or inhabit with ease, social space, 
but also functions as a form of entitlement and belonging. Spaces are claimed through 
enjoyment, an enjoyment that is returned by being witnessed by others. 
 
In light of the cultural significance of emotion we suggest that the growing body of work is 
particularly useful for thinking about the complexity of women’s recovery experiences as 
they negotiated multiple discourses about what they should ‘do’ to move beyond depression 
(Bendelow, 2009; Blackman, 2007; Lyon, 1998).  
 
We conclude our analysis of the limitations of biomedical discourses by highlighting how the 
privileging of anti-depressants in recovery can render invisible the emotion work undertaken 
by women to address depression as a gendered experience. We are not suggesting that the 
interpretation of the emotional self-in-recovery is not a problem free alternative as women’s 
experiences can be interpreted through many power-knowledge relations that may 
individualise accounts of change. Women did draw upon a range of psy-discourses to 
understand their emotional selves (such as, cognitive techniques, identifying a real self or 
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rediscovering a childhood self) in an individual way (Wright, 2003). Yet, many women also 
identified their changing gender expectations, material pressures and negotiation of inequities. 
Although we do not have the space to critically engage with the range of psy-discourses what 
we want to identify is how women’s experience of a different emotional self contributed to 
their own accounts of the recovery.  
 
Understanding the significance of emotion in women’s stories may ‘risk’ reinscribing 
historical gender discourses about emotionality and weakness. However, situated within a 
more critical context we argue that is can open up a space for examining the tensions that 
exist between neurochemical and emotional relations to self and subjecthood. The irony that 
we have identified through this research in the era of pharmaecuticalisation is that despite its 
truth claims anti-depressant medication is largely unable to adequately address to the 
emotional complexity of contemporary subjectivity for women (and also for men with 
different gendered challenges) (see also, Emslie et al., 2008). Our research revealed the 
limitations of biomedical-scientific rationalities that position drug therapies as a thinkable 
solution to the neurochemically deficient self that ‘is’ depressed. Hence, these stories make 
visible women’s experiences as a form of subjugated knowledge about the emotional and 
gendered self. Their insights offer both critique and alternative ways of thinking about 
recovery that could be incorporated into practice and policy domains by reflexive mental 
health professionals. Given the extent of pharmaceuticalisation and the market driven 
imperatives of biomedicine this is no easy task. In this sense, we hope our research 
contributes to the growing number of critical discourses that question the normalisation of 
psychopharmacology and search for alternatives in the areas of women’s health, the mental 
health consumer movement and critical psychiatry/medicine (Blackman, 2007; Davidson, 
2005; Dowrick, 2004; Stavropoulos, 2003). 
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